LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

Search

Simulations Plus Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

20.68 3.82

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

19.83

Max

20.74

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-70M

-67M

Pardavimai

-2.1M

20M

P/E

Sektoriaus vid.

48.528

80.03

Dividendų pajamingumas

0.48

Pelno marža

-330.585

Darbuotojai

243

EBITDA

327K

5.3M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+0.74% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.48%

2.29%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-7M

344M

Ankstesnė atidarymo kaina

16.86

Ankstesnė uždarymo kaina

20.68

Naujienos nuotaikos

By Acuity

56%

44%

310 / 374 reitingas Healthcare

Simulations Plus Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-03 23:21; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

2025-12-03 23:14; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5 Million

2025-12-03 22:01; UTC

Pagrindinės rinkos jėgos

Costco Wholesale Reports Higher Monthly Sales

2025-12-03 21:38; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

2025-12-03 23:59; UTC

Rinkos pokalbiai

Australian Coal Prices Seen Having Recovered Well -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

2025-12-03 23:49; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

2025-12-03 23:13; UTC

Rinkos pokalbiai

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

2025-12-03 23:10; UTC

Uždarbis

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

2025-12-03 23:08; UTC

Rinkos pokalbiai

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

2025-12-03 23:06; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

2025-12-03 22:59; UTC

Įsigijimai, susijungimai, perėmimai

EQB to Buy PC Financial From Loblaw for About $573.5M

2025-12-03 22:45; UTC

Rinkos pokalbiai

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

2025-12-03 22:20; UTC

Uždarbis

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

2025-12-03 22:19; UTC

Uždarbis

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

2025-12-03 22:17; UTC

Uždarbis

Salesforce Working to Add Voice to Agentforce, CEO Says

2025-12-03 22:16; UTC

Uždarbis

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

2025-12-03 22:15; UTC

Uždarbis

Salesforce CEO: Agentforce ARR Was $540M in 3Q

2025-12-03 22:10; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

2025-12-03 22:09; UTC

Įsigijimai, susijungimai, perėmimai

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

2025-12-03 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-12-03 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-03 21:49; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:23; UTC

Uždarbis

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

2025-12-03 21:19; UTC

Uždarbis

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

2025-12-03 21:06; UTC

Uždarbis

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

2025-12-03 21:04; UTC

Uždarbis

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

2025-12-03 21:04; UTC

Uždarbis

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

2025-12-03 21:03; UTC

Uždarbis

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Akcijų palyginimas

Kainos pokytis

Simulations Plus Inc Prognozė

Kainos tikslas

By TipRanks

0.74% į viršų

12 mėnesių prognozė

Vidutinis 20.5 USD  0.74%

Aukščiausias 25 USD

Žemiausias 16 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Simulations Plus Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

5 ratings

3

Pirkti

2

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

310 / 374 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat